Related references
Note: Only part of the references are listed.Osilodrostat in Cushing's disease: The risk of delayed adrenal insufficiency should be carefully monitored
Frederic Castinetti et al.
CLINICAL ENDOCRINOLOGY (2023)
Prolactin Response to Metformin in Cabergoline-Resistant Prolactinomas: A Pilot Study
Luiz Henrique Correa Portari et al.
NEUROENDOCRINOLOGY (2022)
The Future of Somatostatin Receptor Ligands in Acromegaly
Monica R. Gadelha et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)
Somatostatin receptor ligands induce TSH deficiency in thyrotropin-secreting pituitary adenoma
Frederic Illouz et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2021)
Cabergoline should be attempted in progressing non-functioning pituitary macroadenoma
Yona Greenman et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2021)
Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells
Thomas Cuny et al.
PITUITARY (2021)
Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study
G. Beccuti et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2021)
Regulation of the EGFR Pathway by HSP90 Is Involved in the Pathogenesis of Cushing's Disease
Yue Shen et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Approach to the Patient Treated with Steroidogenesis Inhibitors
Frederic Castinetti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
A Hard Look at Cardiac Safety with Dopamine Agonists in Endocrinology Comment
Adrian F. Daly et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Consensus on diagnosis and management of Cushing's disease: a guideline update
Maria Fleseriu et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
New and emerging pharmacological treatment options for acromegaly
Ximene Antunes et al.
EXPERT OPINION ON PHARMACOTHERAPY (2021)
gsp Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly
Luiz Eduardo Wildemberg et al.
CANCERS (2021)
Current opinion on the diagnosis and management of non-functioning pituitary adenomas
Elisa B. Lamback et al.
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM (2021)
Recent Understanding and Future Directions of Recurrent Corticotroph Tumors
Jose Miguel Hinojosa-Amaya et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Pegvisomant treatment in acromegaly in clinical practice: Final results of the French ACROSTUDY (312 patients)
Sara Barraud et al.
ANNALES D ENDOCRINOLOGIE (2021)
Thyrotropin-secreting pituitary adenoma: a structured review of 535 adult cases
Carlien De Herdt et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2021)
Shrinkage by the third month predicts long-term response of macroprolactinoma after cabergoline
Betina Biagetti et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2021)
Drug resistance in pituitary tumours: from cell membrane to intracellular signalling
Erika Peverelli et al.
NATURE REVIEWS ENDOCRINOLOGY (2021)
Aggressive pituitary tumours and pituitary carcinomas
Gerald Raverot et al.
NATURE REVIEWS ENDOCRINOLOGY (2021)
Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results
Artak Labadzhyan et al.
PITUITARY (2021)
Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study
Susan L. Samson et al.
PITUITARY (2021)
Dual effects of 9-cis retinoic acid on ACTH-dependent hyperplastic adrenal tissues
Francesca Pecori Giraldi et al.
SCIENTIFIC REPORTS (2021)
An Update on Pituitary Neuroendocrine Tumors Leading to Acromegaly and Gigantism
Sylvia L. Asa et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Spontaneous coronary artery dissection in association with cabergoline therapy
Zia Saleh et al.
BMJ CASE REPORTS (2021)
Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?
Ken Ho et al.
JOURNAL OF THE ENDOCRINE SOCIETY (2021)
A New Generation Somatostatin-Dopamine Analogue Exerts Potent Antitumoral Actions on Pituitary Neuroendocrine Tumor Cells
Mari C. Vazquez-Borrego et al.
NEUROENDOCRINOLOGY (2020)
A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors
Mari C. Vazquez-Borrego et al.
CLINICAL CANCER RESEARCH (2020)
Cabergoline may act as a radioprotective agent in Cushing's disease
Kunal Thakkar et al.
CLINICAL ENDOCRINOLOGY (2020)
Pituitary-Tumor Endocrinopathies
Shlomo Melmed
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Molecular Mechanisms of Glucocorticoid Resistance in Corticotropinomas: New Developments and Drug Targets
Denis Ciato et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
SST5 expression and USP8 mutation in functioning and silent corticotroph pituitary tumors
Solene Castellnou et al.
ENDOCRINE CONNECTIONS (2020)
TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice
Heather A. Halem et al.
ENDOCRINOLOGY (2020)
Pegvisomant and not somatostatin receptor ligands (SRLs) is first-line medical therapy for acromegaly
Aart J. van der Lely et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2020)
Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase
Rosario Pivonello et al.
LANCET DIABETES & ENDOCRINOLOGY (2020)
Immune Landscape of Pituitary Tumors Reveals Association Between Macrophages and Gonadotroph Tumor Invasion
Moitza Principe et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
The Epidemiology of Pituitary Adenomas
Adrian F. Daly et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2020)
Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide
Susan L. Samson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Multidisciplinary management of acromegaly: A consensus
Andrea Giustina et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2020)
Quantitative Analysis of Somatostatin and Dopamine Receptors Gene Expression Levels in Non-functioning Pituitary Tumors and Association with Clinical and Molecular Aggressiveness Features
Alvaro Flores-Martinez et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
Monica R. Gadelha et al.
ENDOCRINE CONNECTIONS (2020)
Therapeutic Effect of a Novel Chimeric Molecule Targeting Both Somatostatin and Dopamine Receptors on Growth Hormone-Secreting Pituitary Adenomas
Jean Kim et al.
ENDOCRINOLOGY AND METABOLISM (2020)
Advances in the medical treatment of Cushing's syndrome
Richard A. Feelders et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Pasireotide: A potential therapeutic alternative for resistant prolactinoma
Helene Lasolle et al.
ANNALES D ENDOCRINOLOGIE (2019)
Biguanides Exert Antitumoral Actions in Pituitary Tumor Cells Through AMPK-Dependent and -Independent Mechanisms
Mari C. Vazquez-Borrego et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Acromegaly
Annamaria Colao et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients
Adrian F. Daly et al.
ENDOCRINE CONNECTIONS (2019)
MANAGEMENT AND OUTCOMES OF GIANT PROLACTINOMA: A SERIES OF 71 PATIENTS
Oksana Hamidi et al.
ENDOCRINE PRACTICE (2019)
Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively
Chao Tang et al.
CELL DEATH & DISEASE (2019)
Letter to the Editor: Why We Should Still Treat by Neurosurgery Patients With Cushing Disease and a Normal or Inconclusive Pituitary MRI
Frederic Castinetti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Response to Letter to the Editor: Why We Should Still Treat by Neurosurgery Patients With Cushing Disease and a Normal or Inconclusive Pituitary MRI
Olivier Chabre et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Confirmation of a new therapeutic option for aggressive or dopamine agonist-resistant prolactin pituitary neuroendocrine tumors
Gerald Raverot et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2019)
Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma
Eva C. Coopmans et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2019)
Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial
Maria Fleseriu et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Behavioral and steroidogenic pharmacology of phenyl ring substituted etomidate analogs in rats
Megan McGrath et al.
BMC PHARMACOLOGY & TOXICOLOGY (2019)
Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study
Maria Fleseriu et al.
CLINICAL ENDOCRINOLOGY (2019)
Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma A Single-Center, Open-Label, 2-Year Randomized Clinical Trial
Rafael L. Batista et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2019)
Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours
Pedro Marques et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2019)
Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study
Marianne Pavel et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas
Dongyun Zhang et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
A Novel Somatostatin-Dopamine Chimera (BIM23B065) Reduced GH Secretion in a First-in-Human Clinical Trial
Wadim M. de Boon et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Tumor-Directed Therapeutic Targets in Cushing Disease
Marily Theodoropoulou et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
GSTP1 gene methylation and AHR rs2066853 variant predict resistance to first generation somatostatin analogs in patients with acromegaly
F. Ferrau et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2019)
Clinical management of difficult to treat macroprolactinomas
Nicolas Sahakian et al.
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM (2019)
Lapatinib decreases the ACTH production and proliferation of corticotroph tumor cells
Yuko Asari et al.
ENDOCRINE JOURNAL (2019)
Dimethoxy-etomidate: A Nonhypnotic Etomidate Analog that Potently Inhibits Steroidogenesis
Megan McGrath et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2018)
Hepatic safety of ketoconazole in Cushing's syndrome: results of a Compassionate Use Programme in France
Jacques Young et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly
Peter J. Trainer et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
Management of NFAs: medical treatment
Naomi Even-Zohar et al.
PITUITARY (2018)
Combination Treatment with Bromocriptine and Metformin in Patients with Bromocriptine-Resistant Prolactinomas: Pilot Study
Xiaohai Liu et al.
WORLD NEUROSURGERY (2018)
Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial
Andre Lacroix et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Identification of recurrent USP48 and BRAF mutations in Cushing's disease
Jianhua Chen et al.
NATURE COMMUNICATIONS (2018)
Metformin inhibits growth and prolactin secretion of pituitary prolactinoma cells and xenografts
Jun Gao et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
Pre-surgical medical treatment, a major prognostic factor for long-term remission in acromegaly
F. Albarel et al.
PITUITARY (2018)
Treatment of multiresistant prolactinomas with a combination of cabergoline and octreotide LAR
Ernesto Sosa-Eroza et al.
ENDOCRINE (2018)
The Balance of PI3K and ERK Signaling Is Dysregulated in Prolactinoma and Modulated by Dopamine
Allyson K. Roof et al.
ENDOCRINOLOGY (2018)
Metyrapone treatment in Cushing's syndrome: a real-life study
Filippo Ceccato et al.
ENDOCRINE (2018)
Cabergoline for Cushing's disease: a large retrospective multicenter study
A. Ferriere et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2017)
mTOR promotes pituitary tumor development through activation of PTTG1
R. Chen et al.
ONCOGENE (2017)
Diagnosis and Treatment of Pituitary Adenomas A Review
Mark E. Molitch
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study
Andrea Giustina et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Histone Deacetylase Inhibitor SAHA Is a Promising Treatment of Cushing Disease
Jie Lu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Bromocriptine Induces Autophagy-Dependent Cell Death in Pituitary Adenomas
Xin Geng et al.
WORLD NEUROSURGERY (2017)
BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas
Alejandro Ibanez-Costa et al.
SCIENTIFIC REPORTS (2017)
Treatment of a thyrotropin-secreting pituitary adenoma (TSH-oma) with pasireotide LAR
Marlise E. A. van Eersel et al.
CLINICAL ENDOCRINOLOGY (2017)
Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study
Maria Fleseriu et al.
ENDOCRINE (2017)
mTOR Signaling in Growth, Metabolism, and Disease
Robert A. Saxton et al.
CELL (2017)
Cabergoline Tapering Is Almost Always Successful in Patients With Macroprolactinomas
Anne-Cecile Paepegaey et al.
JOURNAL OF THE ENDOCRINE SOCIETY (2017)
EGFR Induces E2F1-Mediated Corticotroph Tumorigenesis
Takako Araki et al.
JOURNAL OF THE ENDOCRINE SOCIETY (2017)
Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study
Donato Iacovazzo et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2016)
Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients
Pia Burman et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2016)
The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas
M. Victoria Recouvreux et al.
JOURNAL OF ENDOCRINOLOGY (2016)
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
Annamaria Colao et al.
PITUITARY (2016)
Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease
Maria Fleseriu et al.
PITUITARY (2016)
Targeting the EGF/HER Ligand-Receptor System in Cancer
Azucena Esparis-Ogando et al.
CURRENT PHARMACEUTICAL DESIGN (2016)
T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly
Iulia Potorac et al.
ENDOCRINE-RELATED CANCER (2016)
Effect of retinoic acid on human adrenal corticosteroid synthesis
Antonella Sesta et al.
LIFE SCIENCES (2016)
The risks of overlooking the diagnosis of secreting pituitary adenomas
Thierry Brue et al.
ORPHANET JOURNAL OF RARE DISEASES (2016)
The Role of Isotretinoin Therapy for Cushing's Disease: Results of a Prospective Study
Lucio Vilar et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2016)
Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly
Ansgar Heck et al.
ENDOCRINE (2016)
Treating prolactinomas with dopamine agonists: always worth the gamble?
Sean Noronha et al.
ENDOCRINE (2016)
Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers
Fredrik Tiberg et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
The Treatment of Cushing's Disease
Rosario Pivonello et al.
ENDOCRINE REVIEWS (2015)
X-linked acrogigantism syndrome: clinical profile and therapeutic responses
Albert Beckers et al.
ENDOCRINE-RELATED CANCER (2015)
Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial
Shlomo Melmed et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients
Eleni Daniel et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas
Zhenye Li et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2015)
A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease
Mathias Riebold et al.
NATURE MEDICINE (2015)
Suppression of mTOR pathway and induction of autophagy-dependent cell death by cabergoline
Shao Jian Lin et al.
ONCOTARGET (2015)
Mutations in the deubiquitinase gene USP8 cause Cushing's disease
Martin Reincke et al.
NATURE GENETICS (2015)
Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial
Jochen Schopohl et al.
PITUITARY (2015)
Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: Might somatostatin analogs have a role as first-line therapy?
Federico Gatto et al.
PITUITARY (2015)
The treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center
Chiara Simeoli et al.
ENDOCRINE (2015)
In Search of a Prognostic Classification of Endocrine Pituitary Tumors
Jacqueline Trouillas
ENDOCRINE PATHOLOGY (2014)
Activation of the Dopamine Receptor Type-2 (DRD2) Promoter by 9-Cis Retinoic Acid in a Cellular Model of Cushing's Disease Mediates the Inhibition of Cell Proliferation and ACTH Secretion Without a Complete Corticotroph-to-Melanotroph Transdifferentiation
Gianluca Occhi et al.
ENDOCRINOLOGY (2014)
THERAPY OF ENDOCRINE DISEASE The challenges in managing giant prolactinomas
Dominique Maiter et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2014)
Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial
Philippe J. Caron et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Long-Term Efficacy and Safety of Pegvisomant in Combination With Long-Acting Somatostatin Analogs in Acromegaly
S. J. C. M. M. Neggers et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis
John D. Carmichael et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Ketoconazole in Cushing's Disease: Is It Worth a Try?
Frederic Castinetti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
LCI699, a Potent 11β-hydroxylase Inhibitor, Normalizes Urinary Cortisol in Patients With Cushing's Disease: Results From a Multicenter, Proof-of-Concept Study
Xavier Bertagna et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Evaluation of growth hormone (GH) action in mice: Discovery of GH receptor antagonists and clinical indications
John J. Kopchick et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2014)
Gigantism and Acromegaly Due to Xq26 Microduplications and GPR101 Mutation
G. Trivellin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
A Novel Suspension Formulation Enhances Intestinal Absorption of Macromolecules Via Transient and Reversible Transport Mechanisms
Shmuel Tuvia et al.
PHARMACEUTICAL RESEARCH (2014)
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial
Monica R. Gadelha et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors
Odelia Cooper et al.
ENDOCRINE (2014)
A Cellular and Molecular Basis for the Selective Desmopressin-Induced ACTH Release in Cushing Disease Patients: Key Role of AVPR1b Receptor and Potential Therapeutic Implications
R. M. Luque et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
A Comprehensive Study of Clinical, Biochemical, Radiological, Vascular, Cardiac, and Sleep Parameters in an Unselected Cohort of Patients With Acromegaly Undergoing Presurgical Somatostatin Receptor Ligand Therapy
Anand K. Annamalai et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
National Incidence and Prevalence of TSH-Secreting Pituitary Adenomas in Sweden
Lisa Onnestam et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in Somatotroph Adenomas Assessed by Monoclonal Antibodies Was Reduced by Octreotide and Correlated With the Acute and Long-Term Effects of Octreotide
Olivera Casar-Borota et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Cabergoline reduces cell viability in non functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion
Teresa Gagliano et al.
PITUITARY (2013)
ZAC1 and SSTR2 Are Downregulated in Non-Functioning Pituitary Adenomas but Not in somatotropinomas
Leonardo Vieria Neto et al.
PLOS ONE (2013)
Evidence for orphan nuclear receptor TR4 in the etiology of Cushing disease
Li Du et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Novel pathway for somatostatin analogs in patients with acromegaly
Monica R. Gadelha et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2013)
Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins
Federico Gatto et al.
CLINICAL ENDOCRINOLOGY (2012)
Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients
Laurent Vroonen et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012)
DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4-and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours
U. Ploeckinger et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012)
Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review
Veronica A. Preda et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012)
Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients
Vanessa Primeau et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012)
Oral Octreotide Absorption in Human Subjects: Comparable Pharmacokinetics to Parenteral Octreotide and Effective Growth Hormone Suppression
S. Tuvia et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Potential Role for Retinoic Acid in Patients with Cushing's Disease
Francesca Pecori Giraldi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Mifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Cushing's Syndrome
Maria Fleseriu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease
Annamaria Colao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly
Andrea Giustina et al.
PLOS ONE (2012)
ERBB2 is a target for USP8-mediated deubiquitination
Inez M. J. Meijer et al.
CELLULAR SIGNALLING (2011)
Positive Prolactin Response to Bromocriptine in 2 Patients with Cabergoline-Resistant Prolactinomas
Pallavi Iyer et al.
Endocrine Practice (2011)
Active and Total Transforming Growth Factor-β1 Are Differentially Regulated by Dopamine and Estradiol in the Pituitary
M. Victoria Recouvreux et al.
ENDOCRINOLOGY (2011)
Somatostatin-Dopamine Chimeras: A Novel Approach to Treatment of Neuroendocrine Tumors
M. D. Culler
HORMONE AND METABOLIC RESEARCH (2011)
Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline
Shlomo Melmed et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Place of Cabergoline in Acromegaly: A Meta-Analysis
Laure Sandret et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas
Hidenori Fukuoka et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Medical treatment of prolactinomas
Annamaria Colao et al.
NATURE REVIEWS ENDOCRINOLOGY (2011)
Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma
Alessandra Fusco et al.
PITUITARY (2011)
Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor
Ning-Ai Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Familial isolated pituitary adenomas experience at a single center: clinical importance of AIP mutation screening
Leandro Kasuki Jomori de Pinho et al.
ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA (2010)
Cabergoline monotherapy in the long-term treatment of Cushing's disease
Ariane Godbout et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010)
Clinical Characteristics and Therapeutic Responses in Patients with Germ-Line AIP Mutations and Pituitary Adenomas: An International Collaborative Study
Adrian F. Daly et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
TSH-secreting adenomas
Paolo Beck-Peccoz et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors
D. Dworakowska et al.
ENDOCRINE-RELATED CANCER (2009)
High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial
Andrea Giustina et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Coexpression of Dopamine and Somatostatin Receptor Subtypes in Corticotroph Adenomas
Christiaan de Bruin et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Expression Analysis of Dopamine Receptor Subtypes in Normal Human Pituitaries, Nonfunctioning Pituitary Adenomas and Somatotropinomas, and the Association between Dopamine and Somatostatin Receptors with Clinical Response to Octreotide-LAR in Acromegaly
Leonardo Vieira Neto et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome
C. de Bruin et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2009)
Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands
George Vlotides et al.
CANCER RESEARCH (2008)
Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly
Philippe Chanson et al.
CLINICAL ENDOCRINOLOGY (2008)
Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study
Tullio Florio et al.
ENDOCRINE-RELATED CANCER (2008)
Medical therapy for clinically non-functioning pituitary adenomas
Annamaria Colao et al.
ENDOCRINE-RELATED CANCER (2008)
Samatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas
Alessandra Fusco et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Prospective Study of High-Dose Cabergoline Treatment of Prolactinomas in 150 Patients
Masami Ono et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Correlation of in Vitro and in Vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy
Diego Ferone et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Beneficial effect of dose escalation of Octreotide-LAR as first-line therapy in patients with acromegaly
Annamaria Colao et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas
Diego Ferone et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion
Maria Chiara Zatelli et al.
ENDOCRINE-RELATED CANCER (2007)
Gammaknife radiosurgery for medically and surgically refractory prolactinomas
Nader Pouratian et al.
NEUROSURGERY (2006)
Pituitary adenoma predisposition caused by germline mutations in the AIP gene
Outi Vierimaa et al.
SCIENCE (2006)
Drug insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women
A Colao et al.
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2006)
Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy
P Jaquet et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
Enhanced protein kinase B/Akt signalling in pituitary tumours
M Musat et al.
ENDOCRINE-RELATED CANCER (2005)
Outcome of cabergoline treatment in men with prolactinoma: Effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis
A Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
PTR-3173 (Somatoprim™), a novel somatostatin analog with affinity for somatostatin receptors 2, 4 and 5 is a potent inhibitor of human GH secretion
I Shimon et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2004)
Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment
A Teramoto et al.
ACTA NEUROPATHOLOGICA (2004)
Dopamine receptor expression and function in corticotroph pituitary tumors
R Pivonello et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells
A Saveanu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile
C Bruns et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2002)
Retinoic acid prevents experimental Cushing syndrome
M Páez-Pereda et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Phosphoinositide-regulated kinases and phosphoinositide phosphatases
NR Leslie et al.
CHEMICAL REVIEWS (2001)
Dopamine D2 receptor gene expression in human adenohypophysial adenomas
L Stefaneanu et al.
ENDOCRINE (2001)
Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: A prospective study in 110 patients
A Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2000)
Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity
M Rocheville et al.
SCIENCE (2000)
Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers
M Rocheville et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
